Production and Purification of Functional Cryptosporidium Glycoproteins by Heterologous Expression in Toxoplasma gondii

Driskell, Iwona M.; O’Connor, Roberta M.

doi:10.1007/978-1-4939-9748-0_6

Search citation statements

Order By: Relevance

Paper Sections

Select...

The Development Of Vaccines Against Cryptosporidium1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of these proteins are being expressed in vectors like Salmonella, recombinant vaccinia, and Lactobacillus (512,551). Others are being expressed in related protozoan parasites such as Toxoplasma gondii (552) or Tetrahymena thermophila (553). In another study, a reverse genetic approach identified three glycosylphophatidylinositol-anchored proteins: GP60, CpH1, and CpSUB1.…”

Section: The Development Of Vaccines Against Cryptosporidiummentioning

confidence: 99%

Controlled Human Infection Models To Accelerate Vaccine Development

et al. 2022

View full text Add to dashboard Cite

The timelines for developing vaccines against infectious diseases are lengthy, and often vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of protective efficacy. The application of controlled human challenge models of infection and disease at the appropriate stages of development could accelerate development of candidate vaccines and, in fact, has done so successfully in some limited cases.

show abstract